SUMMARY
Synaptic protein synthesis is essential for modification of the brain by experience and is aberrant in several genetically defined disorders, notably fragile X (FX), a heritable cause of autism and intellectual disability. Neural activity directs local protein synthesis via activation of metabotropic glutamate receptor 5 (mGlu 5 ), yet how mGlu 5 couples to the intracellular signaling pathways that regulate mRNA translation is poorly understood. Here, we provide evidence that b-arrestin2 mediates mGlu 5 -stimulated protein synthesis in the hippocampus and show that genetic reduction of b-arrestin2 corrects aberrant synaptic plasticity and cognition in the Fmr1 À/y mouse model of FX. Importantly, reducing b-arrestin2 does not induce psychotomimetic activity associated with full mGlu 5 inhibitors and does not affect G q signaling. Thus, in addition to identifying a key requirement for mGlu 5 -stimulated protein synthesis, these data suggest that b-arrestin2-biased negative modulators of mGlu 5 offer significant advantages over first-generation inhibitors for the treatment of FX and related disorders.
INTRODUCTION
Numerous genetic and molecular studies have demonstrated that poorly regulated synaptic protein synthesis downstream of metabotropic glutamate receptor 5 (mGlu 5 ) contributes to the pathophysiology of fragile X (FX), a genetic cause of intellectual disability (ID) and autism spectrum disorder (ASD) (Pop et al., 2014) . This work suggests that targeting mGlu 5 or its downstream effectors may be a fruitful approach for improving the course of FX and other genetic syndromes with shared pathophysiology (Aguilar-Valles et al., 2015; Auerbach et al., 2011; Barnes et al., 2015; Bozdagi et al., 2010; Tian et al., 2015; Wenger et al., 2016) . Indeed, mGlu 5 -based therapies have been immensely successful at correcting FX in animal models (Bhakar et al., 2012) . To date, however, the results of human clinical trials in FX using mGlu 5 negative allosteric modulators (NAMs) have been disappointing (Berry-Kravis et al., 2016; Scharf et al., 2015) .
Although many factors contribute to the challenge of translating findings from animal models to humans, one factor that is common to all drug trials is the therapeutic window-the range of doses that can treat disease pathophysiology without causing negative side effects. In humans, for example, it has been reported that inhibition of mGlu 5 produces dose-limiting psychotomimetic effects (Abou Farha et al., 2014; Pecknold et al., 1982; Porter et al., 2005) . The first-generation mGlu 5 NAMs were identified based on their ability to inhibit G q signaling mediated by phosphoinositide hydrolysis and release of Ca 2+ from intracellular stores (Cosford et al., 2003; Gasparini et al., 1999; Lindemann et al., 2011) . However, available data suggest alternative signaling pathways are central to the regulation of protein synthesis by mGlu 5 (Bhakar et al., 2012; Osterweil et al., 2010; Richter et al., 2015) . Thus, it is possible that therapeutic effects can be enhanced and separated from side effects by selectively targeting the coupling of mGlu 5 to disease-relevant signaling pathways. One pathway that is known to be central to mGlu 5 -stimulated protein synthesis and FX pathophysiology culminates in activation of extracellular signal regulated kinase (ERK)1/2 and the phosphorylation of proteins involved in the regulation of capdependent mRNA translation (Banko et al., 2006; Osterweil et al., 2010 Osterweil et al., , 2013 . Activation of this pathway by mGlu 5 can occur independently of G protein signaling, but how this is achieved has remained a mystery. As is the case for many seven-transmembrane domain receptors, G protein signaling of ligandbound mGlu 5 is terminated by recruitment of b-arrestin to the carboxyl tail of the receptor. In recent years it has become clear that b-arrestin recruitment can also trigger activation of alternative signaling cascades. Of particular relevance is the observation that b-arrestin2 recruitment to the angiotensin II receptor (which, like mGlu 5 , is also G q coupled) stimulates the ERK1/2 pathway and increases mRNA translation rates in both HEK293 and rat vascular smooth muscle cells (Ahn et al., 2009; DeWire et al., 2008) . We therefore hypothesized that b-arrestin2 comprises a crucial link between mGlu 5 and protein synthesis in neurons.
RESULTS
Heterozygous Deletion of b-Arrestin2 Disrupts mGlu 5 -Stimulated ERK Activation and Protein Synthesis without Affecting Gq Signaling To determine the role of b-arrestin2 in mGlu 5 -mediated protein synthesis, we stimulated hippocampal slices from male Arrb2 +/À and wild-type (WT) littermates with a selective agonist and positive modulator of mGlu 5 , 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB; 10 mM, 30 min) and measured the incorporation of 35 S-methionine/cysteine into new protein as described previously (Henderson et al., 2012; Osterweil et al., 2010) . We found that mGlu 5 activation caused a parallel increase in protein synthesis ( Figure 1A ) and ERK1/2 phosphorylation ( Figure 1B ) in WT slices, which were both absent in slices from Arrb2 +/À mice. This blunted response to mGlu 5 stimulation occurred in the absence of differences in basal protein synthesis rates or ERK phosphorylation levels ( Figures 1A and 1B) . We failed to observe a comparable effect on stimulated protein synthesis in Arrb1 +/À mice ( Figure S1 ), suggesting that b-arrestin2 is the relevant isoform for mGlu 5 signaling. From a therapeutic standpoint, it is noteworthy that mGlu 5 -stimulated protein synthesis is abrogated in mice lacking a single allele of Arrb2; a full knockout is not required to see an effect. b-Arrestins have also been shown to participate in additional signaling cascades (DeWire et al., 2007) , including the AktmTOR pathway that has been implicated in the regulation of protein synthesis (Hou and Klann, 2004) and the pathophysiology of FX (Gross et al., 2015; Sharma et al., 2010) . However, in agreement with previous studies in the hippocampal slice (Osterweil et al., 2010) , we found that mGlu 5 activation failed to increase phosphorylation of Akt or ribosomal protein S6, a readout of mTOR activity, in WT mice. These measures of mTOR pathway activity were also unaffected in slices prepared from Arrb1
and Arrb2 +/À mice ( Figure S2 ).
To assay the integrity of G q signaling, we examined calcium mobilization in hippocampal slices from WT and Arrb2 +/À animals using the cell-permeable calcium fluorescent dye Fluo4-AM. We found that a brief application of the agonist S-3,5-dihydroxyphenylglycine (DHPG; 25 mM, 1 min) to slices resulted in a rapid increase in Ca 2+ -mediated fluorescence in area CA1 that was not significantly different between WT and Arrb2 +/À slices ( Figures 1C and 1D ). DHPG was employed in these experiments because it activates both of the G q -coupled metabotropic glutamate receptors, mGlu 1 and mGlu 5 . These DHPGinduced changes in calcium fluorescence were completely blocked by pretreatment with the phospholipase C inhibitor U73122 (data not shown). These results indicate that a partial reduction in b-arrestin2 does not result in aberrant G q signaling in response to mGlu 5 activation. Moreover, they suggest that modulation of mGlu 5 -receptor-mediated protein synthesis can be dissociated from G-protein-dependent signaling via manipulation of b-arrestin2.
Deficient mGlu 5 -Mediated Translation Impairs Synaptic Plasticity in the Hippocampus of Arrb2 +/À Mutants Activation of mGlu 5 results in a form of synaptic long-term depression (LTD) in the hippocampus that requires rapid de novo synaptic protein synthesis (Huber et al., 2000) . We therefore investigated the functional relevance of the observed biochemistry by determining if genetic reduction of Arrb2 also alters the expression and/or protein synthesis dependency of LTD induced with DHPG (25 mM, 5 min) (Huber et al., 2001 ). Basal synaptic transmission was normal ( Figure S3 ), but LTD magnitude was significantly reduced in Arrb2 +/À slices compared to WT (Figures 1E and 1F) . Consistent with previous observations, LTD in WT slices was significantly diminished in the presence of the protein synthesis inhibitor cycloheximide (CHX; 60 mM). In contrast, the residual LTD in slices from Arrb2 +/À animals was unaffected by CHX ( Figures 1E and 1F ). Therefore, we conclude that the protein-synthesis-dependent component of mGlu 5 -mediated LTD is absent in the Arrb2 +/À hippocampus.
In WT mice, the LTD that remains when DHPG is applied in the presence of CHX is expressed via a presynaptic mechanism, revealed by a change in the paired-pulse ratio (Auerbach et al., 2011) . This change in paired-pulse ratio after DHPG was similar in Arrb2 +/À mice, indicating that this presynaptic, protein-synthesis-independent mechanism of LTD is unaffected by reducing signaling through b-arrestin2 ( Figure S3 ). Another mechanistically distinct form of hippocampal LTD can be induced by stimulating NMDA receptors. This type of LTD is expressed postsynaptically but does not require ERK1/2 or immediate translation of mRNA. We found that it is also unaffected by genetic reduction of b-arrestin2 in the hippocampus ( Figure S3 ). Taken together, these results suggest that the diminished LTD magnitude observed in Arrb2 +/À animals is likely a specific consequence of impaired mGlu 5 -stimulated mRNA translation at the synapse.
Decreasing b-Arrestin2 Levels Reverses Synaptic and Behavioral Deficits in a Mouse Model of FX
Our results indicate that b-arrestin2 couples mGlu 5 activation to ERK-dependent protein synthesis and LTD. Aberrantly increased mGlu 5 -dependent protein synthesis observed in vivo (Qin et al., 2005) , brain slices (Dö len et al., 2007; Osterweil et al., 2010) , and synaptoneurosomes (Henderson et al., 2012) is believed to be pathogenic in Fmr1 null mice (Bhakar et al., 2012; Dö len et al., 2007 Figure 3A ). Memory strength was measured as the latency to enter the dark side of a box that was associated with a foot shock. We discovered that Arrb2 +/À as well as Fmr1 À/y mice failed to form a strong association between the context and foot shock (between time 0 and 6 hr), indicating impaired memory acquisition. This is consistent with previous results showing that both excessive and deficient hippocampal protein synthesis can manifest similarly at the behavioral level (Auerbach et al., 2011 Figure S4 . normal memory acquisition and extinction over the course of 48 hr ( Figure 3B ). We also investigated non-aversive object recognition memory. Mice were first allowed to explore an arena with two identical objects for two sessions. The following day, one of the familiar objects was replaced with a novel object ( Figure 3C ). While Fmr1 À/y mice explored both the novel and familiar objects to an equal degree, indicating a severe impairment in novelty detection, Arrb2 +/À 3 Fmr1 À/y mice as well as Arrb2 +/À single mutants showed a strong preference for the novel object similar to WT mice ( Figure 3D ). In an additional series of behavioral experiments, we investigated audiogenic seizures (AGS), as increased susceptibility to AGS is a hallmark phenotype in Fmr1 À/y mice. Genetic reduction of Arrb2 in Fmr1 null mice significantly attenuated seizure incidence ( Figure 3E ), very similar to what has been observed using mGlu 5 and ERK-pathway inhibitors (Dö len et al., 2007; Osterweil et al., 2010; Yan et al., 2005) .
Unlike First-Generation mGlu 5 NAMs, b-Arrestin2 Reduction Does Not Exacerbate MK-801-Induced Hyperlocomotion Our data suggest that the mGlu 5 signaling relevant to FX pathophysiology passes through b-arrestin2 to activate ERK and protein synthesis. If this conclusion is correct, then modulators that specifically target mGlu 5 coupling to b-arrestin2 might avoid side effects that arise from inhibition of G q and/or mTOR pathway signaling. First-generation mGlu 5 NAMs were all identified based on inhibition of G q signaling, and in humans, one adverse side effect reported following treatment with these compounds is derealization and visual hallucinations (Abou Farha et al., 2014; Pecknold et al., 1982; Porter et al., 2005) . Similarly, in mice, mGlu 5 NAMs exacerbate hyperlocomotion in response to treatment with the potent pyschotomimetic MK-801 (Homayoun et al., 2004; Pietraszek et al., 2005) . Therefore, we examined the effect of genetic reduction of b-arrestin2 and mGlu 5 NAM treatment on MK-801-induced hyperlocomotion in mice. We confirmed that pretreatment with the selective mGlu 5 inhibitor 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP) (Cosford et al., 2003) significantly potentiates MK-801-induced hyperlocomotion in WT mice. However, we found that baseline locomotor activity was the same in Arrb2 +/À and WT mice, as was the synergistic effect of MTEP pretreatment on MK-801-induced hyperlocomotion (Figure 4 ). The fact that MTEP continues to exacerbate hyperlocomotion in Arrb2 +/À mice that lack mGlu 5 -regulated protein synthesis suggests that the psychotomimetic effects of the NAM are mediated by inhibition of pathways unrelated to FX pathophysiology. but are unaffected by inhibitors of protein kinase C (PKC) and phospholipase C (PLC) (Fitzjohn et al., 2001; Rush et al., 2002; Schnabel et al., 1999) . It was also known that the ERK pathway is recruited even in the presence of PLC inhibitors (Fitzjohn et al., 2001; Gallagher et al., 2004; Huber et al., 2001 ). However, it was unknown how mGlu 5 can stimulate ERK and protein synthesis independently of G q /PLC activation. We show here that reducing b-arrestin2 completely blocks mGlu 5 -stimulated ERK activation, protein synthesis, and protein-synthesis-dependent LTD but has no effect on G q -dependent mobilization of intracellular Ca 2+ via PLC. Thus, b-arrestin2 couples mGlu 5 to the ERK signaling pathway and protein synthesis in neurons. This conclusion is in accordance with data on ERK pathway activation and the stimulation of protein synthesis by other G q -coupled receptors in non-neuronal cells (Ahn et al., 2009; DeWire et al., 2008) .
A B D C
Our findings also are in general agreement with a contemporaneous investigation of b-arrestin involvement in mGlu 1 and mGlu 5 signaling in the hippocampus (Eng et al., 2016) . This study confirmed our finding of impaired mGlu 5 -dependent synaptic LTD and ERK pathway activation in mice lacking b-arrestin2. One difference is their finding that LTD induced with DHPG (unlike synaptic stimulation) was unaffected in Arrb2 À/À mice.
However, this discrepancy is likely accounted for by the fact that their slices were not sufficiently rested to observe the protein-synthesis-dependent component of agonist-induced LTD (Osterweil et al., 2010) . In any case, both studies are in agreement that protein synthesis-independent DHPG-LTD, expressed by a presynaptic modification, is unaffected by reducing b-arrestin2 ( Figures 1E and 1F) . The discovery that mGlu 5 stimulates protein synthesis via b-arrestin2 has clinical as well as basic biological significance. One core pathophysiology of FX is believed to be excessive synaptic protein synthesis downstream of mGlu 5 (Bhakar et al., 2012) . In animal models of FX, it has been shown that inhibition of mGlu 5 can correct a wide array of mutant phenotypes. This work led directly to human FX clinical trials with mGlu 5 inhibitors, but, unfortunately, the results of these trials to date have disappointed (Berry-Kravis et al., 2016) . With all drug trials, the maximum allowable dosage is determined by the occurrence of adverse side effects. In the case of first-generation mGlu 5 drugs, a potentially serious dose-limiting psychiatric side effect is derealization and visual hallucinations. To separate the therapeutic effect of mGlu 5 inhibition (suppression of protein synthesis) from the unwanted side effects, it is essential to understand the mechanism that specifically couples mGlu 5 to the ERK signaling pathway. The correction of multiple FX phenotypes, including excessive basal protein synthesis, in Fmr1 À/y mice crossed with b-arrestin2 heterozygous mice indicates that b-arrestin2 is a key component of a pathogenic pathway. Further, the fact that MK-801 induced hyperlocomotion is still augmented in the Arrb2 +/À mice by MTEP, a first-generation NAM with high selectivity for mGlu 5 (Cosford et al., 2003) , indicates that this undesirable effect of inhibiting mGlu 5 -G q signaling is likely to be pharmacologically separable from the therapeutic effect of inhibiting mGlu 5 -b-arrestin2 signaling. G-protein-coupled receptors respond to a wide variety of signals and initiate a large number of distinct cellular signaling pathways. This versatility has made these receptors attractive targets for pharmacological therapies, and over 50% of the current drugs used clinically target these receptors (Insel et al., 2007) . The finding that b-arrestin-and G protein-dependent cellular signaling are pharmacologically separable has opened a new vista for the treatment of disease. For some disorders, modulation of only one of these signaling pathways may be therapeutically beneficial, while the others could mediate undesirable and possibly conflicting outcomes (Whalen et al., 2011) . Our findings suggest that the use of mGlu 5 modulators for the treatment of FX is a case in point. There is little doubt that b-arrestin-biased allosteric modulators of mGlu receptors are feasible (Hathaway et al., 2015; Iacovelli et al., 2014; Sheffler et al., 2011) , and their development could lead to the next generation of drugs for the treatment of FX and several other genetically defined causes of ID and ASD (Aguilar-Valles et al., 2015; Auerbach et al., 2011; Barnes et al., 2015; Bozdagi et al., 2010; Tian et al., 2015; Wenger et al., 2016) .
Because it is a monogenic disorder, FX has emerged in recent years as a bellwether for the utility of developing medicines for psychiatric diseases by reproducing genetic etiologies in animal models to identify pathophysiology and therapeutic targets. The current study is important, because it reveals some of the previously unappreciated limitations of targeting mGlu 5 signaling via G q and suggests an exciting alternative approach.
EXPERIMENTAL PROCEDURES

Arrb2
+/À male and female mutant mice on the C57BL/6J clonal background were mated to produce the WT and Arrb2 +/À offspring used in this study.
Fmr1
À/+ female mice (Jackson Laboratory) were crossed with Arrb2 +/À male mice to generate double-mutant animals. All experimental animals were age-matched male littermates and were studied with the experimenter blind to genotype and treatment condition. All experimental techniques were approved by the Institutional Animal Care and Use Committee at Massachusetts Institute of Technology (MIT), and all animals were treated in accordance with National Institutes of Health (NIH) and MIT guidelines. Hippocampal slice preparation, electrophysiological recordings, metabolic labeling, immunoblotting inhibitory avoidance, and audiogenic seizure assays were performed as previously described (Auerbach et al., 2011; Dö len et al., 2007; Osterweil et al., 2010) and are detailed in Supplemental Experimental Procedures. Slices were stimulated with the selective agonist/positive modulator of mGlu 5 CDPPB for metabolic labeling and immunoblotting or the group 1 mGluR agonist (S)-DHPG for electrophysiology and calcium imaging experiments. Calcium mobilization was assessed using the cell-permeable calcium fluorescent dye Fluo4-AM in the presence of tetrodotoxin (TTX) and AP-5. The effect of MTEP on MK-801-induced hyperlocomotion was assessed using Plexon'sCinePlex Studio and custom written MATLAB software. Two-way ANOVAs with post hoc two-tailed t tests or Bonferroni's test for multiple comparisons were used to determine differences between genotypes and drug treatments unless stated otherwise. All data shown represent mean ± SEM. A full description of the experimental procedures can be found in Supplemental Experimental Procedures. 
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